Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMEY-001
- Development stage
- Preclinical
- Lead developer
- Jianmin Pharmaceutical Group
- Modality
- Small Molecules
01
Overview
JMEY-001 is an investigational drug candidate being developed by Jianming Pharmaceutical Group (Wuhan Jianming Pharmaceutical) for the treatment of epilepsy. According to the company's research and development pipeline, the agent is currently in the clinical stage of development. While specific details regarding its molecular target, mechanism of action, and chemical structure have not been publicly disclosed, it represents a key component of the company's expansion into central nervous system (CNS) therapeutic areas. The 'JMEY' prefix in the code name likely refers to the developer (Jianming) and the target indication (Epilepsy).
Beyond the preview
Go deeper on JMEY-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMEY-001.